2024
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Hodan R, Gupta S, Weiss J, Axell L, Burke C, Chen L, Chung D, Clayback K, Felder S, Foda Z, Giardiello F, Grady W, Gustafson S, Hagemann A, Hall M, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz A, Prats M, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder N, Shibata D, Stanich P, Swanson B, Szymaniak B, Welborn J, Wiesner G, Yurgelun M, Dwyer M, Darlow S, Diwan Z. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 695-711. PMID: 39689429, DOI: 10.6004/jnccn.2024.0061.Peer-Reviewed Original ResearchConceptsMultigene panel testingPathogenic/likely pathogenic variantsGenetic/Familial High-Risk AssessmentColon cancer screeningColon cancer riskHigh risk of cancerNCCN Clinical Practice GuidelinesClinical practice guidelinesRisk of cancerPanel testingHigh riskPathogenic variantsPeutz-Jeghers syndromeLynch syndromeCancer screeningDe-implementationCancer riskEndometrial cancerPTEN hamartoma tumor syndromeHigh-risk assessmentPractice guidelinesHamartoma tumor syndromePeutz-JeghersNCCN GuidelinesCHEK2Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN GuidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability
2018
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Provenzale D, Gupta S, Ahnen D, Markowitz A, Chung D, Mayer R, Regenbogen S, Blanco A, Bray T, Cooper G, Early D, Ford J, Giardiello F, Grady W, Hall M, Halverson A, Hamilton S, Hampel H, Klapman J, Larson D, Lazenby A, Llor X, Lynch P, Mikkelson J, Ness R, Slavin T, Sugandha S, Weiss J, Dwyer M, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 939-949. PMID: 30099370, DOI: 10.6004/jnccn.2018.0067.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorColonoscopyColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesHumansImmunochemistryMass ScreeningMedical OncologyMiddle AgedOccult BloodRandomized Controlled Trials as TopicSeptinsSocieties, MedicalTime FactorsTomography, X-Ray ComputedUnited StatesConceptsColorectal cancerNCCN GuidelinesRecommended screening strategySporadic colorectal cancerAverage-riskNCCN panelScreening modalitiesNCCN Guidelines InsightsScreening individualsIncreased-riskScreening strategiesNCCNGuidelinesRelevant dataIndividualsColorectalModalitiesPrimary focusScreeningRecommendationsReview commentsCancerFocusNCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Choi M, Clemens M, Dogan A, Greer J, Halwani A, Haverkos B, Hoppe R, Jacobsen E, Jagadeesh D, Kim Y, Lunning M, Mehta A, Mehta-Shah N, Oki Y, Olsen E, Pro B, Rajguru S, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer M, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 123-135. PMID: 29439173, DOI: 10.6004/jnccn.2018.0007.Peer-Reviewed Original ResearchConceptsExtranodal NK/T-cell lymphomaNK/T-cell lymphomaNatural killer (NK)/T-cell lymphomaSubtype of non-Hodgkin lymphomaNon-Hodgkin's lymphomaT-cell lymphomaNCCN Guidelines InsightsUpper aerodigestive tractManagement of patientsNasal typeNK/T-cellRare malignancyStandard therapyNCCN GuidelinesAerodigestive tractT cellsLymphomaRandomized trialsPatientsNCCNMalignancyRegimensTherapySubtypesDiagnosis